INMB
INmune Bio·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
INMB fundamentals
INmune Bio (INMB) released its earnings on Oct 30, 2025: revenue was 0 (YoY 0.00%), beat estimates; EPS was -0.24 (YoY +60.00%), beat estimates.
Revenue / YoY
0
0.00%
EPS / YoY
-0.24
+60.00%
Report date
Oct 30, 2025
INMB Earnings Call Summary for Q3,2025
- CORDStrom Regulatory Momentum: U.K. MAA filing on track for Q2 2026; independent trial analysis shows consistent efficacy in reducing systemic inflammation and itch in RDEB.
- XPro Alzheimer's Progress: Phase II data demonstrates cognitive and biomarker improvements in high-inflammation patients; FDA end-of-Phase II meeting in Q1 2026.
- Financial Stability: $27.7M cash runway supports 2026 milestones; R&D expenses down 52% YoY.
- Strategic Differentiation: CORDStrom's systemic anti-inflammatory mechanism and cost-effective manufacturing position it as a leader in rare disease cell therapy.
EPS
Revenue
Revenue & Expenses
Key Indicators
INmune Bio (INMB) key financial stats and ratios, covering profitability, financial health, and leverage.
INmune Bio (INMB)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
INmune Bio (INMB)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
INmune Bio (INMB)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does INmune Bio (INMB) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track INmune Bio (INMB) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
Did INmune Bio beat or miss consensus estimates last quarter?What is the revenue and EPS growth rate for INmune Bio year over year?What does INmune Bio do and what are its main business segments?What were the key takeaways from INmune Bio's earnings call?What were the key takeaways from INmune Bio’s earnings call?What guidance did INmune Bio's management provide for the next earnings period?What is INmune Bio's gross profit margin?What factors drove the changes in INmune Bio's revenue and profit?
